ECSP11011201A - Combinaciones que comprenden metotrexato e inhibidores de dhodh - Google Patents
Combinaciones que comprenden metotrexato e inhibidores de dhodhInfo
- Publication number
- ECSP11011201A ECSP11011201A EC2011011201A ECSP11011201A ECSP11011201A EC SP11011201 A ECSP11011201 A EC SP11011201A EC 2011011201 A EC2011011201 A EC 2011011201A EC SP11011201 A ECSP11011201 A EC SP11011201A EC SP11011201 A ECSP11011201 A EC SP11011201A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- alkyl
- groups
- cycloalkyl
- halogen atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención proporciona una combinación que comprende (a) metotrexato y (b) un inhibidor de DHODH no hepatotóxico de fórmula (I):donde:R1 se selecciona del grupo que consiste en átomos de hidrógeno, átomos de halógeno, alquilo C1-4, cicloalquilo C3-4, -CF3 y -OCF3,R2 se selecciona del grupo que consiste en átomos de hidrógeno, átomos de halógeno y grupos alquilo C1-4,R3 se selecciona del grupo que consiste en grupos -COOR5, -CONHR5, tetrazolilo, -SO2NHR5 y -CONHSO2R5, donde R5 se selecciona del grupo que consiste en un átomo de hidrógeno y grupos alquilo C1-4 lineales o ramificados,R4 se selecciona del grupo que consiste en un átomo de hidrógeno y un grupo alquilo C1-4, R9 se selecciona del grupo que consiste en un átomo de hidrógeno y un grupo fenilo,G1 representa un grupo seleccionado de N y CR6 donde R6 se selecciona del grupo que consiste en átomos de hidrógeno, átomos de halógeno, alquilo C1-4, cicloalquilo C3-4 , alcoxi C1-4, -CF3, -OCF3, heteroarilo C5-7 monocíclico que contiene N , grupos heterociclilo C3-7 monocíclicos que contienen N y grupos arilo C6-10, estando estos grupos arilo C6-10 opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halógeno y grupos alquilo C1-4, G2 representa un grupo seleccionado de:" un átomo de hidrógeno, un grupo hidroxi, un átomo de halógeno, un grupo cicloalquilo C3-4, un grupo alcoxi C1-4 y -NRaRb, dondeRa representa un grupo alquilo C1-4 y Rb se selecciona de un grupo que consiste en grupo alquilo C1-4 y grupo alcoxi C1-4-alquilo C1-4, oRa y Rb junto con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico saturado de 6 a 8 miembros que contiene opcionalmente un átomo de oxígeno como heteroátomo adicional," un anillo heteroaromático de 5 a 10 miembros, monocíclico o bicíclico, que contiene uno o más átomos de nitrógeno que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, alquilo C1-4, alcoxi C1-4, cicloalquilo C3-4, cicloalcoxi C3-4, -CF3, -OCF3, y -CONR7R8, donde R7 y R8 se seleccionan, independientemente, de átomo de hidrógeno, grupos alquilo C1-4 lineales o ramificados, grupos cicloalquilo C3-7, o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un grupo de fórmuladonde n es un número entero de 0 a 3," un grupo fenilo que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos alquilo C1-4, hidroxilo, alcoxi C1-4, cicloalquilo C3-4, cicloalcoxi C3-4, ciano, -CF3, -OCF3, -CONR7R8, oxadiazolilo, triazolilo, pirazolilo e imidazolilo, estando los grupos oxadiazolilo, triazolilo, pirazolilo e imidazolilo opcionalmente sustituidos con grupos alquilo C1-4 o cicloalquilo C3-7 y donde R7 y R8 se seleccionan, independientemente, de átomo de hidrógeno, grupos alquilo C1-4 lineales o ramificados, grupos cicloalquilo C3-7, o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un grupo de fórmuladonde n es un número entero de 0 a 3o, cuando G1 representa CR6, G2 junto con R6 forma un grupo carbocíclico C5-10 no aromático o un grupo arilo C6-10,y sus sales y N-óxidos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382006A EP2210615A1 (en) | 2009-01-21 | 2009-01-21 | Combinations comprising methotrexate and DHODH inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011201A true ECSP11011201A (es) | 2011-08-31 |
Family
ID=40790917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011201A ECSP11011201A (es) | 2009-01-21 | 2011-07-13 | Combinaciones que comprenden metotrexato e inhibidores de dhodh |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20110280831A1 (es) |
| EP (2) | EP2210615A1 (es) |
| JP (1) | JP2012515737A (es) |
| KR (1) | KR20110117658A (es) |
| CN (1) | CN102292108A (es) |
| AR (1) | AR075036A1 (es) |
| AU (1) | AU2010206334A1 (es) |
| BR (1) | BRPI1005169A2 (es) |
| CA (1) | CA2748400A1 (es) |
| CL (1) | CL2011001760A1 (es) |
| CO (1) | CO6341575A2 (es) |
| EA (1) | EA201101098A1 (es) |
| EC (1) | ECSP11011201A (es) |
| IL (1) | IL213625A0 (es) |
| MX (1) | MX2011007446A (es) |
| NZ (1) | NZ593413A (es) |
| PE (1) | PE20120552A1 (es) |
| SG (2) | SG196826A1 (es) |
| TW (1) | TW201029652A (es) |
| UA (1) | UA104449C2 (es) |
| UY (1) | UY32380A (es) |
| WO (1) | WO2010083975A1 (es) |
| ZA (1) | ZA201104259B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| EP2444086A1 (en) * | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US20140031383A1 (en) | 2011-02-08 | 2014-01-30 | Dana-Farber Cancer Institute, Inc. | Methods for treatment of melanoma |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| WO2013031831A1 (ja) * | 2011-08-30 | 2013-03-07 | 富山化学工業株式会社 | 関節リウマチなどの自己免疫疾患の治療の改善方法 |
| WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
| GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
| EP3858361A4 (en) | 2018-09-28 | 2021-12-01 | FUJIFILM Corporation | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE |
| EP4190402A4 (en) * | 2020-07-30 | 2023-10-25 | FUJIFILM Corporation | HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR SALT THEREOF, APPLICATION THEREOF, AND INTERMEDIATE THEREOF |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226869A (en) * | 1979-02-02 | 1980-10-07 | American Cyanamid Company | Method of stimulating the immune response with halogenated 10-(ω-dialkylaminopolymethyleneamino)-2-methoxypyrido[3,2-b]quinolines |
| DE69617431T2 (de) | 1995-06-21 | 2002-08-01 | Asta Medica Ag | Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| WO2008058288A2 (en) * | 2006-11-09 | 2008-05-15 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) * | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
-
2009
- 2009-01-21 EP EP09382006A patent/EP2210615A1/en not_active Withdrawn
-
2010
- 2010-01-11 UY UY0001032380A patent/UY32380A/es unknown
- 2010-01-13 TW TW099100843A patent/TW201029652A/zh unknown
- 2010-01-19 WO PCT/EP2010/000270 patent/WO2010083975A1/en active Application Filing
- 2010-01-19 MX MX2011007446A patent/MX2011007446A/es not_active Application Discontinuation
- 2010-01-19 SG SG2014003388A patent/SG196826A1/en unknown
- 2010-01-19 AU AU2010206334A patent/AU2010206334A1/en not_active Abandoned
- 2010-01-19 UA UAA201110006A patent/UA104449C2/uk unknown
- 2010-01-19 BR BRPI1005169A patent/BRPI1005169A2/pt not_active IP Right Cessation
- 2010-01-19 EA EA201101098A patent/EA201101098A1/ru unknown
- 2010-01-19 JP JP2011546677A patent/JP2012515737A/ja not_active Ceased
- 2010-01-19 NZ NZ593413A patent/NZ593413A/en not_active IP Right Cessation
- 2010-01-19 CA CA2748400A patent/CA2748400A1/en not_active Abandoned
- 2010-01-19 EP EP10701206.4A patent/EP2389197B1/en active Active
- 2010-01-19 PE PE2011001295A patent/PE20120552A1/es not_active Application Discontinuation
- 2010-01-19 SG SG2011048337A patent/SG172453A1/en unknown
- 2010-01-19 KR KR1020117016969A patent/KR20110117658A/ko not_active Application Discontinuation
- 2010-01-19 CN CN2010800051639A patent/CN102292108A/zh active Pending
- 2010-01-19 US US13/145,628 patent/US20110280831A1/en not_active Abandoned
- 2010-01-20 AR ARP100100123A patent/AR075036A1/es not_active Application Discontinuation
-
2011
- 2011-06-08 ZA ZA2011/04259A patent/ZA201104259B/en unknown
- 2011-06-16 IL IL213625A patent/IL213625A0/en unknown
- 2011-07-13 EC EC2011011201A patent/ECSP11011201A/es unknown
- 2011-07-15 CO CO11088762A patent/CO6341575A2/es active IP Right Grant
- 2011-07-20 CL CL2011001760A patent/CL2011001760A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG196826A1 (en) | 2014-02-13 |
| UA104449C2 (uk) | 2014-02-10 |
| CL2011001760A1 (es) | 2012-03-09 |
| AU2010206334A1 (en) | 2011-07-07 |
| IL213625A0 (en) | 2011-07-31 |
| CA2748400A1 (en) | 2010-07-29 |
| EP2389197B1 (en) | 2014-06-18 |
| BRPI1005169A2 (pt) | 2019-09-24 |
| JP2012515737A (ja) | 2012-07-12 |
| NZ593413A (en) | 2013-12-20 |
| US20110280831A1 (en) | 2011-11-17 |
| EP2389197A1 (en) | 2011-11-30 |
| KR20110117658A (ko) | 2011-10-27 |
| UY32380A (es) | 2010-02-26 |
| SG172453A1 (en) | 2011-07-28 |
| CN102292108A (zh) | 2011-12-21 |
| TW201029652A (en) | 2010-08-16 |
| MX2011007446A (es) | 2011-08-03 |
| ZA201104259B (en) | 2012-02-29 |
| WO2010083975A1 (en) | 2010-07-29 |
| AR075036A1 (es) | 2011-03-02 |
| EP2210615A1 (en) | 2010-07-28 |
| PE20120552A1 (es) | 2012-05-21 |
| CO6341575A2 (es) | 2011-11-21 |
| EA201101098A1 (ru) | 2012-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011201A (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| AR067886A1 (es) | Derivados de acido azabifenilaminobenzoico | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| UY39338A (es) | Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR084277A1 (es) | Compuestos utiles para el tratamiento del sida | |
| ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| ECSP11011365A (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh | |
| DOP2012000318A (es) | Compuestos heterociclicos fusionados | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR070648A1 (es) | Derivados de bencimidazol sustituido | |
| AR075253A1 (es) | Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene. | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. |